Literature DB >> 30344899

Drivers of Orphan Drug Development.

Ana Mingorance1.   

Abstract

Previously neglected by the pharmaceutical industry, rare diseases and orphan drugs are rapidly becoming mainstream. Both market forces and technology enablers are responsible for this migration and combine to create multiple business approaches. This viewpoint discusses the drivers that attract different companies into this booming orphan drug space.

Year:  2018        PMID： 30344899      PMCID： PMC6187403          DOI： 10.1021/acsmedchemlett.8b00438

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  7 in total

1.  Orphan drug development: an economically viable strategy for biopharma R&D.

Authors:  Kiran N Meekings; Cory S M Williams; John E Arrowsmith
Journal:  Drug Discov Today       Date:  2012-02-17       Impact factor: 7.851

Review 2.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 3.  Orphan drugs: the regulatory environment.

Authors:  Pedro Franco
Journal:  Drug Discov Today       Date:  2012-09-05       Impact factor: 7.851

4.  The impact of genomics on the future of medicine and health.

Authors:  John S Mattick; Marie A Dziadek; Bronwyn N Terrill; Warren Kaplan; Allan D Spigelman; Frank G Bowling; Marcel E Dinger
Journal:  Med J Aust       Date:  2014-07-07       Impact factor: 7.738

Review 5.  The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.

Authors:  Ashish Kumar Kakkar; Neha Dahiya
Journal:  Drug Dev Res       Date:  2014-05-14       Impact factor: 4.360

6.  Promising gene therapies pose million-dollar conundrum.

Authors:  Erika Check Hayden
Journal:  Nature       Date:  2016-06-16       Impact factor: 49.962

Review 7.  New Therapeutic Uses for Existing Drugs.

Authors:  Bobbie Ann Austin; Ami D Gadhia
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622
  7 in total
  2 in total

1.  Novel Therapies for Orphan Diseases.

Authors:  José M García Fernández; Carmen Ortiz Mellet
Journal:  ACS Med Chem Lett       Date:  2019-06-18       Impact factor: 4.345

2.  Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems.

Authors:  Nayoung Han; Jung Mi Oh; In-Wha Kim
Journal:  Ther Clin Risk Manag       Date:  2021-08-21       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.